TRACON Pharmaceuticals, Inc.

213 articles about TRACON Pharmaceuticals, Inc.

• TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment

  11/20/2023

  TRACON Pharmaceuticals, Inc. announced it has licensed its proprietary PDP of CRO-independent clinical research to a clinical stage biotech company for a $3.0 million upfront payment.

• TRACON Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

  11/9/2023

  TRACON Pharmaceuticals, Inc. announced financial results for the third quarter ended September 30, 2023.

• TRACON to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 9, 2023

  10/31/2023

  TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its third quarter 2023 financial and operating results after the close of U.S. financial markets on Thursday, November 9, 2023.

• TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned

  9/18/2023

  TRACON Pharmaceuticals announced that the ENVASARC Phase 2 pivotal trial more than satisfied the futility threshold of 3 responses out of 46 based on the results of the second and final mandated independent data monitoring committee efficacy review, and the trial will continue as planned.

• TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences

  9/5/2023

  TRACON Pharmaceuticals, Inc. (Nasdaq: TCON) announced today that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will participate at the following upcoming investor conferences and provide a company overview:

• TRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

  8/14/2023

  TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the second quarter ended June 30, 2023.

• TRACON to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 14, 2023

  8/2/2023

  TRACON Pharmaceuticals, Inc. (Nasdaq: TCON) announced today that it will report its second quarter 2023 financial and operating results after the close of U.S. financial markets on Monday, August 14, 2023.

• TRACON Pharmaceuticals Announces Collection of Arbitration Award from I-Mab Biopharma

  7/11/2023

  TRACON Pharmaceuticals announced it has collected the previously announced arbitration award from I-Mab Biopharma.

• TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial

  6/20/2023

  TRACON Pharmaceuticals (NASDAQ: TCON) today announced the positive results of a six-month independent data monitoring committee (IDMC) review for the ongoing ENVASARC Phase 2 pivotal trial.

• TRACON Pharmaceuticals to Present at the Maxim Group Healthcare Virtual Conference

  6/16/2023

  TRACON Pharmaceuticals, Inc. announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the Maxim Group Healthcare Virtual Conference on Tuesday, June 20, 2023 at 3:30 pm Eastern Time.

• TRACON Pharmaceuticals Announces Enforcement Action to Collect Binding Arbitration Award from I-Mab Biopharma

  6/15/2023

  TRACON Pharmaceuticals, Inc. announced that it has commenced court proceedings in Hong Kong and the Cayman Islands to enforce an April 2023 arbitration award against I-Mab for approximately $23.0 million, plus interest.

• TRACON Pharmaceuticals to Present at the 2023 Jefferies Healthcare Conference

  6/2/2023

  TRACON Pharmaceuticals, Inc. announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 8:30 am Eastern Time.

• TRACON Pharmaceuticals Announces Poster Presentations for Envafolimab and TRC102 at the 2023 ASCO Annual Meeting

  5/30/2023

  TRACON Pharmaceuticals (NASDAQ: TCON) today announced the presentation of two posters at the upcoming American Society of Clinical Oncology (ASCO) 2023 annual meeting, being held June 2-6, 2023.

• TRACON Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

  5/10/2023

  TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced financial results for the first quarter ended March 31, 2023.

• TRACON to Report First Quarter 2023 Financial Results and Provide Corporate Update on May 10, 2023

  5/3/2023

  TRACON Pharmaceuticals, Inc. (Nasdaq: TCON) announced today that it will report its first quarter 2023 financial and operating results after the close of U.S. financial markets on Wednesday, May 10, 2023.

• TRACON Pharmaceuticals Announces Arbitration Award in Dispute with I-Mab

  4/25/2023

  TRACON Pharmaceuticals, Inc. today announced that the tribunal in the arbitration against I-Mab conducted under the Rules of Arbitration of the International Chamber of Commerce (ICC) rendered an award to TRACON in the aggregate amount of approximately $23.0 million.

• TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

  3/8/2023

  TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the fourth quarter and year ended December 31, 2022.

• TRACON to Report Fourth Quarter and Year-End 2022 Financial Results and Provide Corporate Update on March 8, 2023

  2/28/2023

  TRACON Pharmaceuticals, Inc. announced that it will report its fourth quarter and year-end 2022 financial and operating results after the close of U.S. financial markets on Wednesday, March 8, 2023.

• TRACON Pharmaceuticals Announces up to $30M Non-Recourse Non-Dilutive Financing Related to Arbitration Award Decision Expected in Q1 2023

  12/27/2022

  TRACON Pharmaceuticals, a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced entry into an up to $30 million non-recourse financing agreement.

• TRACON Pharmaceuticals Announces Positive Results Based on Double-Digit Objective Response Rate in Each Cohort from the Ongoing ENVASARC Phase 2 Pivotal Trial

  12/14/2022

  TRACON Pharmaceuticals (NASDAQ: TCON) today announced the IDMC for the ongoing ENVASARC Phase 2 pivotal trial recommended continued accrual as planned in both cohorts: single agent envafolimab and envafolimab in combination with Yervoy (ipilimumab).